


## Jolkinolide B Datasheet

4<sup>th</sup> Edition (Revised in July, 2016)**[ Product Information ]****Name:** Jolkinolide B**Catalog No.:** CFN90245**Cas No.:** 37905-08-1**Purity:** >=98%**M.F:** C<sub>20</sub>H<sub>26</sub>O<sub>4</sub>**M.W:** 330.42**Physical Description:** Powder**Synonyms:** (4aR,6aS,7aβ,10aR)-1,2,3,4,4aα,5,6,11aβ,11bα,11c-Decahydro-4,4,8,11cβ-tetramethylbisoxireno[1,10a:3,4]Phenanthro[3,2-b]furan-9(7aH)-one.**[ Intended Use ]**

1. Reference standards;
2. Pharmacological research;
3. Synthetic precursor compounds;
4. Intermediates & Fine Chemicals;
5. Others.

**[ Source ]**The herbs of *Stellera chamaejasme* Linn.**[ Biological Activity or Inhibitors ]**

Jolkinolide B can induce neuroendocrine differentiation of human prostate LNCaP cancer cell line.<sup>[1]</sup>

Jolkinolide B can induce apoptosis in MDA-MB-231 cells through inhibition of the PI3K/Akt signaling pathway.<sup>[2]</sup>

Jolkinolide B exhibits significant antitumor activity, it is able to enhance apoptosis of human leukemic HL-60 and THP-1 cells, at least in part, through downregulation of JAK2/STAT3 and bcl-2, and upregulation of Bax and cytosolic cytochrome c. <sup>[3]</sup>

Jolkinolide B has potent anti-inflammatory activities, the mechanism may be attributed to its suppression of NF-κB and activation.<sup>[4]</sup>

### **[ Solvent ]**

Chloroform, Dichloromethane, Ethyl Acetate, DMSO, Acetone, etc.

### **[ HPLC Method ]<sup>[5]</sup>**

Mobile phase: Acetonitrile- H<sub>2</sub>O= 75:25;

Flow rate: 1.0 ml/min;

Column temperature: Room Temperature;

The wave length of determination: 250 nm.

### **[ Storage ]**

2-8°C, Protected from air and light, refrigerate or freeze.

### **[ References ]**

[1] Liu W K, Ho J C, Qin G, *et al. Biochem. Pharmacol.*, 2002, 63(5):951-7.

[2] Lin Y, Cui H, Xu H, *et al. Oncol. Reports*, 2012, 27(6):1976-80.

[3] Wang J H, Zhang K, Niu H Y, *et al. Int. J. Clin. Pharm. Th.*, 2012, 51(3):170-8.

[4] Yang H, Li Y, Huo P, *et al. Int. Immunopharmacol.*, 2015, 26(1):119-24.

[5] Qiao C, Han Q, He Z, *et al. Chinese Journal of Pharmaceutical Analysis*, 2006,

26(9):1204-6.

## **[ Contact ]**

**Address:**

S5-3 Building, No. 111, Dongfeng Rd.,  
Wuhan Economic and Technological Development Zone,  
Wuhan, Hubei 430056,  
China

**Email:** [info@chemfaces.com](mailto:info@chemfaces.com)

**Tel:** +86-27-84237783

**Fax:** +86-27-84254680

**Web:** [www.chemfaces.com](http://www.chemfaces.com)

**Tech Support:** [service@chemfaces.com](mailto:service@chemfaces.com)